LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water. It has a novel mode of... It has a novel mode of action combining both the light effect of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and antagonism at mu-opioid receptors.
- Mechanism
- Curator reviewed
LI 301 has a novel mode of action combining both the light effect of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and antagonism at mu-opioid receptors.
- Primary indication
- Investigated for use/treatment in premature ejaculation.Curator reviewed
- Code names
- LI-301
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with LI-301, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account